The pathogenic role of P2RX7 in MS progression (and neurodegeneration in general) is also supported by P2RX7 genetic polymorphism (47–49), where gain-of-function variants are observed at higher frequencies and hypomorphic variants at lower frequencies in different neurodegenerative diseases but also in faster aging (50). This evidence concerns the gene P2RX7 and myeloid sarcoma.